MA30816B1 - Agent prophylactique ou therapeutique pour le cancer - Google Patents
Agent prophylactique ou therapeutique pour le cancerInfo
- Publication number
- MA30816B1 MA30816B1 MA31823A MA31823A MA30816B1 MA 30816 B1 MA30816 B1 MA 30816B1 MA 31823 A MA31823 A MA 31823A MA 31823 A MA31823 A MA 31823A MA 30816 B1 MA30816 B1 MA 30816B1
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- protein
- prophylactic
- therapeutic agent
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UN ANTICORPS MONOCLONAL HUMAIN DIRIGÉ CONTRE UNE PROTÉINE AYANT UNE SÉQUENCE D'ACIDES AMINÉS QUI EST LA MÊME OU ESSENTIELLEMENT LA MÊME QUE LA SÉQUENCE D'ACIDES AMINÉS DÉCRITE DANS LA SEQ ID NO : 1 OU 3, UN PEPTIDE PARTIEL DE LA PROTÉINE, OU UN SEL DE LA PROTÉINE. L'ANTICORPS MONOCLONAL HUMAIN EST UTILE COMME AGENT PROPHYLACTIQUE OU THÉRAPEUTIQUE POUR LE CANCER, PROMOTEUR DE L'APOPTOSE DE LA CELLULE CANCÉREUSE, INHIBITEUR DE LA PROLIFÉRATION DE LA CELLULE CANCÉREUSE, AGENT CYTOTOXIQUE POUR UNE CELLULE CANCÉREUSE QUI UTILISE UN MÉCANISME DE BIODÉFENSE VIA UNE RÉGION FC D'UN ANTICORPS, OU ÉQUIVALENTS.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2006/320429 WO2007043635A1 (fr) | 2005-10-07 | 2006-10-06 | Agent préventif/remède pour le cancer |
ARP070101453A AR060362A1 (es) | 2005-10-07 | 2007-04-04 | Agente para prevenir / tratar el cancer |
JP2007100876 | 2007-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30816B1 true MA30816B1 (fr) | 2009-10-01 |
Family
ID=44083820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31823A MA30816B1 (fr) | 2006-10-06 | 2009-04-27 | Agent prophylactique ou therapeutique pour le cancer |
Country Status (21)
Country | Link |
---|---|
US (1) | US20100008928A1 (fr) |
EP (1) | EP2067791A4 (fr) |
JP (1) | JPWO2008044754A1 (fr) |
KR (1) | KR20090078339A (fr) |
CN (1) | CN101541834A (fr) |
AR (1) | AR063153A1 (fr) |
AU (1) | AU2007307536A1 (fr) |
BR (1) | BRPI0717024A2 (fr) |
CA (1) | CA2666249A1 (fr) |
CL (1) | CL2007002879A1 (fr) |
CO (1) | CO6190538A2 (fr) |
EC (1) | ECSP099276A (fr) |
IL (1) | IL197389A0 (fr) |
MA (1) | MA30816B1 (fr) |
MX (1) | MX2009003126A (fr) |
NO (1) | NO20091783L (fr) |
PE (1) | PE20081456A1 (fr) |
RU (1) | RU2009117237A (fr) |
TN (1) | TN2009000090A1 (fr) |
TW (1) | TW200823235A (fr) |
WO (1) | WO2008044754A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011352205B2 (en) * | 2010-12-31 | 2016-06-16 | Bioatla, Llc | Express humanization of antibodies |
MX348578B (es) * | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |
KR20150018604A (ko) * | 2012-06-06 | 2015-02-23 | 온코메드 파마슈티칼스, 인크. | 히포 경로를 조절하는 결합제 및 그의 용도 |
WO2014069681A1 (fr) * | 2012-10-29 | 2014-05-08 | 인제대학교 산학협력단 | Anticorps ciblant le cancer et composition permettant de prévenir ou de traiter le cancer en contenant |
WO2014069682A1 (fr) * | 2012-10-29 | 2014-05-08 | 인제대학교 산학협력단 | Anticorps ciblant le cancer et composition permettant de prévenir ou de traiter le cancer en contenant |
PT3258951T (pt) | 2015-02-19 | 2020-08-18 | Compugen Ltd | Anticorpos anti-pvrig e métodos de utilização |
US10550173B2 (en) | 2015-02-19 | 2020-02-04 | Compugen, Ltd. | PVRIG polypeptides and methods of treatment |
JO3620B1 (ar) * | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
LT3347379T (lt) | 2016-08-17 | 2020-05-11 | Compugen Ltd. | Anti-tigit antikūnai, anti-pvrig antikūnai ir jų kombinacijos |
EP3548071A4 (fr) | 2016-11-30 | 2020-07-15 | OncoMed Pharmaceuticals, Inc. | Méthodes de traitement du cancer comprenant des agents de liaison à tigit |
KR20200021474A (ko) | 2017-06-01 | 2020-02-28 | 컴퓨젠 엘티디. | 삼중 조합 항체 치료제 |
CA3106114A1 (fr) | 2018-07-20 | 2020-01-23 | Surface Oncology, Inc. | Compositions anti-cd112r et procedes |
EP4277904A1 (fr) | 2021-01-15 | 2023-11-22 | Seagen Inc. | Conjugués anticorps-médicament immunomodulateurs |
WO2022170002A1 (fr) | 2021-02-03 | 2022-08-11 | Seagen Inc. | Composés et conjugués immunostimulateurs |
WO2023161943A1 (fr) * | 2022-02-28 | 2023-08-31 | Nectin Therapeutics Ltd. | Anticorps humanisés dirigés contre la nectine-2 et conjugués médicamenteux de ceux-ci |
WO2023215740A1 (fr) | 2022-05-06 | 2023-11-09 | Seagen Inc. | Conjugués anticorps-médicament immunomodulateurs |
WO2024030577A1 (fr) | 2022-08-03 | 2024-02-08 | Seagen Inc. | Conjugués anti-pd-l1-médicament immunostimulateurs |
EP4321522A1 (fr) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Composés cytotoxiques et conjugués de ceux-ci |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
AU4228699A (en) | 1998-06-03 | 1999-12-20 | Northwestern University | Cellular proteins which mediate herpesvirus entry |
US20030129685A1 (en) * | 1998-10-28 | 2003-07-10 | Jian Ni | 12 human secreted proteins |
DE19852800C1 (de) | 1998-11-16 | 2000-04-13 | Univ Albert Ludwigs Freiburg | Verfahren zur Herstellung von Antikörpern gegen ein Polypeptid, von dem die kodierende Nukleinsäure bekannt ist |
US20030022279A1 (en) * | 1999-06-14 | 2003-01-30 | Fraser Christopher C. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
WO2002000677A1 (fr) | 2000-06-07 | 2002-01-03 | Human Genome Sciences, Inc. | Acides nucleiques, proteines et anticorps |
AU1305302A (en) | 2000-10-05 | 2002-04-15 | Immunex Corp | Nectin polypeptides, polynucleotides, methods of making and use thereof |
US20050112568A1 (en) | 2001-06-05 | 2005-05-26 | Lori Friedman | Dgks as modifiers of the p53 pathwha and methods of use |
EP1392111A4 (fr) | 2001-06-06 | 2004-07-28 | Regeneron Pharma | Procede de ciblage de locus actifs sur le plan de la transcription |
US20030084468A1 (en) | 2001-09-05 | 2003-05-01 | Economides Aris N. | Methods of expressing transgenes |
EP1571968A4 (fr) * | 2002-04-16 | 2007-10-17 | Genentech Inc | Compositions et methodes permettant de diagnostiquer et de traiter une tumeur |
AU2003295328A1 (en) | 2002-10-02 | 2004-04-23 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP1733743A4 (fr) * | 2004-04-09 | 2007-06-27 | Takeda Pharmaceutical | Agents de prevention/remedes contre le cancer |
-
2007
- 2007-10-04 MX MX2009003126A patent/MX2009003126A/es not_active Application Discontinuation
- 2007-10-04 KR KR1020097009036A patent/KR20090078339A/ko not_active Application Discontinuation
- 2007-10-04 BR BRPI0717024-6A2A patent/BRPI0717024A2/pt not_active IP Right Cessation
- 2007-10-04 EP EP07829644A patent/EP2067791A4/fr not_active Withdrawn
- 2007-10-04 PE PE2007001348A patent/PE20081456A1/es not_active Application Discontinuation
- 2007-10-04 AU AU2007307536A patent/AU2007307536A1/en not_active Abandoned
- 2007-10-04 CN CNA2007800371476A patent/CN101541834A/zh active Pending
- 2007-10-04 CA CA002666249A patent/CA2666249A1/fr not_active Abandoned
- 2007-10-04 US US12/444,382 patent/US20100008928A1/en not_active Abandoned
- 2007-10-04 JP JP2008538759A patent/JPWO2008044754A1/ja not_active Withdrawn
- 2007-10-04 WO PCT/JP2007/069908 patent/WO2008044754A1/fr active Application Filing
- 2007-10-04 RU RU2009117237/10A patent/RU2009117237A/ru not_active Application Discontinuation
- 2007-10-05 TW TW096137411A patent/TW200823235A/zh unknown
- 2007-10-05 CL CL200702879A patent/CL2007002879A1/es unknown
- 2007-10-09 AR ARP070104425A patent/AR063153A1/es unknown
-
2009
- 2009-03-03 IL IL197389A patent/IL197389A0/en unknown
- 2009-03-16 TN TN2009000090A patent/TN2009000090A1/fr unknown
- 2009-04-23 EC EC2009009276A patent/ECSP099276A/es unknown
- 2009-04-27 MA MA31823A patent/MA30816B1/fr unknown
- 2009-05-04 CO CO09044621A patent/CO6190538A2/es not_active Application Discontinuation
- 2009-05-05 NO NO20091783A patent/NO20091783L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JPWO2008044754A1 (ja) | 2010-02-18 |
BRPI0717024A2 (pt) | 2014-03-11 |
AU2007307536A1 (en) | 2008-04-17 |
CN101541834A (zh) | 2009-09-23 |
MX2009003126A (es) | 2009-04-06 |
CL2007002879A1 (es) | 2008-06-27 |
CO6190538A2 (es) | 2010-08-19 |
ECSP099276A (es) | 2009-06-30 |
US20100008928A1 (en) | 2010-01-14 |
CA2666249A1 (fr) | 2008-04-17 |
EP2067791A4 (fr) | 2009-11-25 |
TW200823235A (en) | 2008-06-01 |
AR063153A1 (es) | 2008-12-30 |
PE20081456A1 (es) | 2008-11-27 |
IL197389A0 (en) | 2011-08-01 |
RU2009117237A (ru) | 2010-11-20 |
NO20091783L (no) | 2009-07-01 |
TN2009000090A1 (en) | 2010-08-19 |
AU2007307536A2 (en) | 2009-04-30 |
WO2008044754A1 (fr) | 2008-04-17 |
EP2067791A1 (fr) | 2009-06-10 |
KR20090078339A (ko) | 2009-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30816B1 (fr) | Agent prophylactique ou therapeutique pour le cancer | |
Kuriyan et al. | X-ray structure of trypanothione reductase from Crithidia fasciculata at 2.4-A resolution. | |
AR113225A2 (es) | Anticuerpo monoclonal aislado que se une específicamente a cxcr4 humano expresado sobre la superficie de una célula y que es capaz de inducir apoptosis de célula tumorales cxcr4⁺ in vivo | |
Juillerat-Jeanneret et al. | Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase? | |
WO2021019246A1 (fr) | Complexes peptidiques bicycliques hétérotandems | |
US20210101937A1 (en) | Heterotandem bicyclic peptide complexes | |
EP3514167B1 (fr) | Peptide de liaison à la thrombospondine 1 | |
NZ610566A (en) | Antibody purification | |
CN111819202A (zh) | 释放区段及包含其的结合组合物 | |
AR119080A1 (es) | Proteínas multiespecíficas | |
JP2012512185A (ja) | 膜1型マトリックス金属タンパク質阻害剤およびその使用 | |
GEP20115324B (en) | Tweak binding antibodies | |
Wong et al. | Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma | |
JP2020073562A (ja) | 抗nme抗体 | |
WO2018027329A1 (fr) | CONJUGUÉS D'ANTAGONISTES DE TGF-β. | |
Amar et al. | Clinical implications of compounds designed to inhibit ECM‐modifying metalloproteinases | |
US7374898B2 (en) | Peptide inhibitors against seprase | |
KR20120084298A (ko) | 펩티드 제거제 | |
Kim et al. | Identification of four new angiotensin I-converting enzyme inhibitory peptides from fermented anchovy sauce | |
Bissonnette et al. | Proteomic analysis and immunodetection of the bovine milk osteopontin isoforms | |
US10905750B2 (en) | GRP78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents | |
JP2011507498A5 (fr) | ||
Glenn et al. | Trypanocidal effect of α′, β′-epoxyketones indicates that trypanosomes are particularly sensitive to inhibitors of proteasome trypsin-like activity | |
Dahan et al. | Dipeptidyl peptidase IV as a potential target for selective prodrug activation and chemotherapeutic action in cancers | |
RU2584572C2 (ru) | Способ получения полипептида, конъюгированного с поли(этиленгликолевым) фрагментом, нуклеиновая кислота и слитый полипептид, предназначенные для применения в способе |